Fri, Jul 11, 2014, 10:54 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

GASFRAC Energy Services, Inc. Message Board

budtuba 264 posts  |  Last Activity: 8 hours ago Member since: Jun 30, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    No more short weeks until September

    by mocwwwrb 9 hours ago

    If Belviq continues the upwards trend this will debunk all the posts that people don't try to lose weight in the summer months. Even SO alluded to this as a means to moderate expectations. The big problem with analyzing IMS or Symphony data is that does not indicate the number of prescriptions made that week, but the number of prescriptions filled that week. Depending on the urgency of patients to get their prescriptions, the actual sales could lag by several days into a following week. Therefore, I have argued that a moving average of two weeks's data will show a better trend than one week's or per working day calculated from one week data divided by the number of work days. As far as pharmacies are concerned, most of them work 6 days a week and some even for 7 days. In today's competitive environment, drug stores cannot compete if they close one day a week,,,including pharmacy staff. On the other hand, many doctors take off an additional day per week therefore only available to prescribe medicines (new indications) for four days per week. The IMS and Symphony data just cannot analyze that factor.

    I also keep wondering when big stock buyers will believe the promise of Belviq to buy more as long investors. It is just too broad a brush to label big buyers as "Wall Street", for many of "Wall Street" traders have alternative strategies, like options, options against holdings, high frequency trading deals, and hedging their longs. I will be impressed when the instutional ownership goes up above 60% (NOW 44% reported by Etrade)

    ryt5

    Sentiment: Strong Buy

  • The approved dosage of Q was the mid-dose and it had very similar efficacy to B. Consequently, when starting on Q, a prescription to the mid-dose makes more sense until a patient has shown no major side effects. This method of dose adjustment with time is not necessary with B.

    ryt5

    Sentiment: Strong Buy

  • budtuba budtuba Jul 8, 2014 2:59 PM Flag

    If any chemical compound has a new indication for treating a disease, you can patent it for that treatment. Sometimes, chemical compounds differ by the molecular structure and not the elements used to create it. Organic compounds are very prone to alternate molecular structures that react differently.

    ryt5

    Sentiment: Strong Buy

  • Reply to

    Rep. Cassidy (R) - Sponsor of HR 2415

    by qmingin Jul 8, 2014 1:22 PM
    budtuba budtuba Jul 8, 2014 2:40 PM Flag

    We all need to contact our own congressmen representing our state and ask for support of HR2415. Once this is approved throught the Senate, it is at least 16 months before it becomes effective.

    ryt5

    Sentiment: Strong Buy

  • From the IV Board:

    CoreLife adds BELVIQ as a treatment option
    Posted on June 29, 2014 | By Winston C Lucas

    Dr. Stephan Izzi, Medical Director at CoreLife has recently approved the selective use of BELVIQ as part of a treatment program for certain overweight adults with a weight-related medical problem, or obese adults. Belviq is the first FDA-approved weight-loss medication in more than a decade and has proven very successful in clinical trials.

    According to Ryan Ebersole, Director of Operations at CoreLife, “Patients that have been prescribed Belviq have experienced excellent results when combined with a healthy diet and exercise program.” In fact, all of the CoreLife programs center around a lifestyle change to include regular exercise and a healthy diet. “BELVIQ is an excellent tool, however medication alone is not the answer to permanent weight loss.”

    In Clinical Studies:

    Almost half of people (47.1%) taking BELVIQ® lost 5% or more of their body weight after 1 year of treatment, compared with those using diet and exercise alone (22.6%) Some (22.4%) lost as much as 10% of their body weight after 1 year of treatment, compared with those using diet and exercise alone (8.7%)
    ---------------------------
    Note that Belviq removes the insatiable desire for eating that is the cause of obesity and why weight loss is so difficult for heavy people.

    ryt5

    Sentiment: Strong Buy

  • budtuba budtuba Jul 4, 2014 10:44 AM Flag

    BS .#$%$ backwards short = trohs

    ryt5

    Sentiment: Strong Buy

  • budtuba budtuba Jul 4, 2014 10:42 AM Flag

    To repeat the observation by oolong_long:

    "No one like Jack Lief dedicates his life to the health sciences and then suddenly becomes a stock market fraud to steal investors' money. That's an absurd notion fabricated by lying and distorting short sellers of this stock, nothing more."

    Obviously, being a FORMER scientist suggests he sold out on the dedication in order make money. True scientists lives for truth and honest disclosure of facts.

    ryt5

    Sentiment: Strong Buy

  • Reply to

    Arena CEO Leif Founded the Company 12 Years Ago

    by unquoted1 Jul 3, 2014 11:51 PM
    budtuba budtuba Jul 4, 2014 10:36 AM Flag

    Their strategy from day 1 was to develop new drugs using the then new science of receptor stimulation or shielding by designing new molecules to interact with them. This MEANT to find other companies to partner with for the marketing, and to avoid takeovers by other pharmas which would have stifled their choices of what new drugs to pursue. People who invested in Arena with this awareness are concert with this strategy.

    ryt5

    Sentiment: Strong Buy

  • budtuba budtuba Jul 3, 2014 8:59 AM Flag

    Great info...thanks for sharing it.

    ryt5

    Sentiment: Strong Buy

  • budtuba budtuba Jul 3, 2014 8:37 AM Flag

    Spencer Osbourne has clearly stated he is invested long in ARNA. I believe he is, for if not, his credibility for any future articles would be permanently jeopardized. That is what you are suggesting, and just for that reason: to discredit him. He has been the source of scripts' data that is accurateand consistent with other sources (IV Board), and he has applied a good argument that people should not expect a blockbuster sales' response for this year. I am an engineer with years of statistical experiment desing experience and see his arguments as sound and honestly presented. He has stated that approvals in Canada, Mexico, Brazil, Switzerland, and Europe will have a positive influence. What is your bone over his analysis?

    In conclusion, your question is reasonable, your conclusion is not.

    ryt5

    Sentiment: Strong Buy

  • Reply to

    LISTEN TO WELLS FARGO CONFRENCE AGAIN!!!!

    by jahjarha9rahajh Jul 2, 2014 12:44 PM
    budtuba budtuba Jul 2, 2014 5:18 PM Flag

    Bump it up.

    ryt5

    Sentiment: Strong Buy

  • Reply to

    This can be a factor for the next rally

    by mocwwwrb Jul 2, 2014 9:51 AM
    budtuba budtuba Jul 2, 2014 5:16 PM Flag

    Bump it up. A good trend to watch for.

    ryt4

    Sentiment: Strong Buy

  • budtuba budtuba Jul 2, 2014 5:08 PM Flag

    He also said their patent strategy team is top notch in dealing with the USPTO in extending patents when unexpected results manifest.

    Sentiment: Strong Buy

  • budtuba budtuba Jul 2, 2014 4:54 PM Flag

    Wow...sounds like a fun drug to inject daily doses:

    BRAND NAME: Victoza

    DRUG CLASS AND MECHANISM: Liraglutide is an injectable drug that reduces the level of sugar (glucose) in the blood. It is used for treating type 2 diabetes and is similar to exenatide (Byetta). Liraglutide belongs in a class of drugs called incretin mimetics because these drugs mimic the effects of incretins. Incretins, such as human-glucagon-like peptide-1 (GLP-1), are hormones that are produced and released into the blood by the intestine in response to food. GLP-1 increases the secretion of insulin from the pancreas, slows absorption of glucose from the gut, and reduces the action of glucagon. (Glucagon is a hormone that increases glucose production by the liver.) All three of these actions reduce levels of glucose in the blood. In addition, GLP-1 reduces appetite. Liraglutide is a synthetic (man-made) hormone that resembles and acts like GLP-1. In studies, liraglutide treated patients achieved lower blood glucose levels and experienced weight loss. Liraglutide was approved by the FDA in January 2010.

    SIDE EFFECTS: The most common side effects of liraglutide are nausea, vomiting, diarrhea, constipation, upper respiratory tract infection, and headache. Patients also may experience flu like symptoms, dizziness, sinusitis, back pain, and reactions at the injection site.
    ---------------------------
    Note that "nausea, vomiting, diarrhea, constipation" will reduce appetite.

    ryt5

    Sentiment: Strong Buy

  • budtuba budtuba Jul 2, 2014 4:41 PM Flag

    No other partner is now POSSIBLE.

    Sentiment: Strong Buy

  • budtuba budtuba Jul 2, 2014 4:08 PM Flag

    Already approved drugs do not have any action unless a unknown bad side effect shows up. That won't happen with Belviq. In fact, actual weight loss data is beating the clinical trial data.

    ryt5

    Sentiment: Strong Buy

  • budtuba budtuba Jul 2, 2014 4:05 PM Flag

    Corecction...most doctors nd patients don't know about it and may be confused with Qysmia that had issues and required a startup period to reach full dosage.

    ryt5

    Sentiment: Strong Buy

  • budtuba budtuba Jul 2, 2014 4:03 PM Flag

    Relatively old news...in today's world, but:

    Abstract
    Lorcaserin, a selective 5-hydroxytryptamine2C (5-HT2C) agonist, has been shown to facilitate weight loss in obese populations. It was assessed for its efficacy in reducing nicotine self-administration in young adult female Sprague-Dawley rats. The effect of short-term doses (subcutaneous) on nicotine self-administration (0.03 mg/kg per infusion) with a fixed ratio 1 schedule was assessed in 3-h sessions. Short-term lorcaserin doses (0.3125–20 mg/kg) were administered in a counterbalanced order. Significant reduction of nicotine self-administration was achieved with all of the short-term doses in this range. Tests of lorcaserin on locomotor activity detected prominent sedative effects at doses greater than 1.25 mg/kg with more modest transient effects seen at 0.625 to 1.25 mg/kg. Long-term effects of lorcaserin on locomotor activity were tested with repeated injections with 0.625 mg/kg lorcaserin 10 times over 2 weeks. This low lorcaserin dose did not cause an overall change in locomotor activity relative to that of saline-injected controls. Long-term lorcaserin (0.625 mg/kg) significantly reduced nicotine self-administration over a 2-week period of repeated injections. Long-term lorcaserin at this same dose had no significant effects on food self-administration over the same 2-week period of repeated injections. These studies support development of the 5-HT2C agonist lorcaserin to aid tobacco smoking cessation.

    ryt5

    Sentiment: Strong Buy

  • budtuba budtuba Jul 2, 2014 1:53 PM Flag

    You must be unfamilar with what Columbus believed. He thought he could reach the spices of the Far East by sailing west. Once he discovered the Caribean islands, he ramped up his marketing plan to Isabella and made two more voyage. That first trip was the breakthrough....the world was round.. You could say was analogous to Arena discovering lorcaserin hydrochloride (now Belviq) but proving the technology of receptor interaction with chronic diseases like obesity, diabetes II, thrombosis, pain. You have the opportunity of being the modern Isabella and approving more research and rewards will follow big time.

    ryt5

    Sentiment: Strong Buy

  • budtuba budtuba Jul 2, 2014 1:46 PM Flag

    You must have some sleepless nights over this to observe the frequency of ads both day and night.

    ryt5

    Sentiment: Strong Buy

GSFVF
1.66+0.02(+1.03%)Jul 11 3:26 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Potbelly Corporation
NasdaqGSFri, Jul 11, 2014 4:00 PM EDT
ACI Worldwide, Inc.
NasdaqGSFri, Jul 11, 2014 4:00 PM EDT
MGIC Investment Corp.
NYSEFri, Jul 11, 2014 4:01 PM EDT